The Palliative Performance Scale has been shown to predict survival among hospice and palliative medicine patients in the outpatient and inpatient clinical settings, where lower PPS scores are directly related to shorter survival. We seek to evaluate if this relationship persists among a racially diverse, older adult population when assessed at the time of admission from the emergency department.
Subjects are being asked to volunteer for a research study because they have been diagnosed with Alzheimer's disease. Alzheimer's dementia is the most common form of dementia. It is a general term for memory loss and loss of other intellectual abilities that are serious enough to interfere with daily activities.
The purpose of this study is to see if the investigational drug, LY3314814 (study drug) can slow the progression of your Alzheimer's disease. In Part I of the study, subjects will either receive the study drug or placebo. After 78 weeks, all subjects will begin Part II where everyone is on the study drug.
This is a study of brain aging and Mild Cognitive Impairment (MCI). In this study, we use non-invasive brain MRI techniques and tests of memory and other thinking skills to improve the detection of brain diseases of aging at the very earliest stages. A fasting blood draw will also be performed to help clarify the contribution of blood sugar and cholesterol to brain aging. We are primarily recruiting 80 individuals ages 65-85 who have been diagnosed with Mild Cognitive Impairment (MCI) by their healthcare provider. We are also recruiting individuals ages 65-85 who are cognitively healthy and do not have any significant or unstable medical conditions. This study is sponsored by the NIH and is conducted at MUSC.
If you are interested in this study, please contact us by phone or through: http://bit.ly/MIND-study
This study is designed to examine the effects and safety of citalopram in patients with Alzheimer's disease experiencing agitation or emotional disturbance. This study is 9 weeks long. In order to participate in this study, you must be at least 45 years old, have Alzheimer's disease and experience agitation. Participants cannot have depression. Participants may stay on approved memory medications for Alzheimer's disease.